title: Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.
abstract: Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have K(i) value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (K(i) 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects.
authors.affiliation: Chemistry and the Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, New York, USA.
authors.forename: William T
authors.initials: WT
authors.lastname: Berger
authors.forename: Brian P
authors.initials: BP
authors.lastname: Ralph
authors.forename: Martin
authors.initials: M
authors.lastname: Kaczocha
authors.forename: Jing
authors.initials: J
authors.lastname: Sun
authors.forename: Trent E
authors.initials: TE
authors.lastname: Balius
authors.forename: Robert C
authors.initials: RC
authors.lastname: Rizzo
authors.forename: Samir
authors.initials: S
authors.lastname: Haj-Dahmane
authors.forename: Iwao
authors.initials: I
authors.lastname: Ojima
authors.forename: Dale G
authors.initials: DG
authors.lastname: Deutsch
mesh_terms: D000700:Analgesics / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use*; D001095:Arachidonic Acids / Q000378:metabolism*; D001692:Biological Transport; D002352:Carrier Proteins / Q000378:metabolism*; D055808:Drug Discovery; D063388:Endocannabinoids / Q000378:metabolism*; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism*; D006801:Humans; D051379:Mice; D053284:Polyunsaturated Alkamides / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D001095:Arachidonic Acids; D002352:Carrier Proteins; D063388:Endocannabinoids; C493412:FABP5 protein, human; C107608:FABP7 protein, human; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D053284:Polyunsaturated Alkamides; D025521:Tumor Suppressor Proteins; C078814:anandamide